Annexon Inc (ANNX)
4.73
+0.28
(+6.29%)
USD |
NASDAQ |
Apr 25, 13:20
Annexon Cash from Financing (TTM): 135.52M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 135.52M |
September 30, 2023 | 18.03M |
June 30, 2023 | 140.70M |
March 31, 2023 | 140.47M |
December 31, 2022 | 122.91M |
September 30, 2022 | 123.75M |
June 30, 2022 | 1.007M |
March 31, 2022 | 1.546M |
December 31, 2021 | 1.795M |
Date | Value |
---|---|
September 30, 2021 | 0.847M |
June 30, 2021 | 260.70M |
March 31, 2021 | 361.72M |
December 31, 2020 | 360.88M |
September 30, 2020 | 360.03M |
June 30, 2020 | 129.49M |
March 31, 2020 | 27.82M |
December 31, 2019 | 28.40M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
0.847M
Minimum
Sep 2021
361.72M
Maximum
Mar 2021
130.33M
Average
123.75M
Median
Sep 2022
Cash from Financing (TTM) Benchmarks
Trxade Health Inc | 1.406M |
P3 Health Partners Inc | 100.33M |
Arrowhead Pharmaceuticals Inc | 2.744M |
Insmed Inc | 168.44M |
Heron Therapeutics Inc | 54.11M |